Cgrp Inhibitor Market

CGRP Inhibitor Market Overview

As per MRFR analysis, the CGRP Inhibitor Market Size was estimated at 2.13 USD Billion in 2022. The CGRP Inhibitor Market Industry is expected to grow from 2.39 USD Billion in 2023 to 6.8 USD Billion by 2032. The CGRP Inhibitor Market CAGR (growth rate) is expected to be around 12.33% during the forecast period (2024 - 2032).

Key CGRP Inhibitor Market Trends Highlighted

CGRP Inhibitors are on the rise, especially due to the increased awareness and prevalence of migraine disorders which can be seen as a notable market trend. The development of technologically advanced and more potent drugs expands the treatment repertoire as well as improves patient outcomes. The strengthening of partnerships between pharmaceutical companies and research institutes enhances the development of new drugs.

In addition, government programs to expand access to medical care and increase insurance coverage are contributing to the growth of new niches in the market for CGRP Inhibitors.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

CGRP Inhibitor Market Drivers

Rising Prevalence of Migraines and Cluster Headaches

Migraines and cluster headaches are debilitating conditions that affect millions of people worldwide. The rising prevalence of these conditions is a major driver of growth in the CGRP Inhibitor Market Industry. CGRP Inhibitors are a new class of drugs that have been shown to be effective in preventing and treating migraines and cluster headaches.

As the prevalence of these conditions continues to rise, the demand for CGRP Inhibitors is expected to grow accordingly. CGRP Inhibitors work by blocking the activity of calcitonin gene-related peptide (CGRP), a neuropeptide that is involved in the transmission of pain signals. CGRP is released during migraine and cluster headache attacks.

It is thought to play a role in the development of these conditions. By blocking the activity of CGRP, CGRP Inhibitors can help to prevent and treat migraines and cluster headaches. The rising prevalence of migraines and cluster headaches is a major public health concern. These conditions can cause significant pain and disability.

They can have a negative impact on quality of life. The development of CGRP Inhibitors has provided a new treatment option for these conditions, and it is expected to have a significant impact on the CGRP Inhibitor Market Industry in the coming years.

Increased Awareness of CGRP Inhibitors

The increased awareness of CGRP Inhibitors is another major driver of growth in the CGRP Inhibitor Market Industry. CGRP Inhibitors are a relatively new class of drugs, and many people are still unaware of their benefits. As awareness of CGRP Inhibitors grows, it is expected to lead to increased demand for these drugs.

There are a number of factors that are contributing to the increased awareness of CGRP Inhibitors. One factor is the growing number of clinical trials that are being conducted on these drugs. These trials are providing evidence of the efficacy and safety of CGRP Inhibitors, which is helping to raise awareness of these drugs among healthcare professionals and patients.

Another factor that is contributing to the increased awareness of CGRP Inhibitors is the growing number of patient advocacy groups that are being formed. These groups are working to raise awareness of CGRP Inhibitors and to provide support to patients who are using these drugs. The increased awareness of CGRP Inhibitors is expected to continue to drive growth in the CGRP Inhibitor Market Industry in the coming years.

Expanding Label Indications

The expanding label indications for CGRP Inhibitors are another major driver of growth in the CGRP Inhibitor Market Industry. CGRP Inhibitors were initially approved for the treatment of migraines and cluster headaches. However, recent studies have shown that these drugs may also be effective in treating other conditions, such as chronic pain and fibromyalgia.

The expanding label indications for CGRP Inhibitors are expected to lead to increased demand for these drugs. As more and more conditions are treated with CGRP Inhibitors, the market for these drugs is expected to grow accordingly. The CGRP Inhibitor Market Industry is expected to grow significantly in the coming years.

The rising prevalence of migraines and cluster headaches, the increased awareness of CGRP Inhibitors, and the expanding label indications for these drugs are all major drivers of growth in this market.

CGRP Inhibitor Market Segment Insights

CGRP Inhibitor Market Type of Inhibitor Insights

The CGRP Inhibitor Market is segmented by Type of Inhibitor into Monoclonal Antibodies, Small Molecules, and Peptides. Monoclonal Antibodies dominated the market in 2023, accounting for a revenue share of over 60%. The dominance of monoclonal antibodies can be attributed to their high specificity and efficacy in blocking CGRP receptors.

Small molecules, on the other hand, are expected to witness the fastest growth over the forecast period, owing to their ease of administration and lower cost compared to monoclonal antibodies. The growth of the market is attributed to the increasing prevalence of migraine and cluster headache, rising awareness about CGRP Inhibitors, and the launch of new and innovative products.

Key players in the CGRP Inhibitor Market include Amgen, Eli Lilly and Company, Teva Pharmaceutical Industries, and Allergan. These companies are investing heavily in research and development to develop new and improved CGRP Inhibitors. The CGRP Inhibitor Market is expected to witness significant growth in the coming years, driven by the increasing prevalence of migraine and cluster headache, the rising awareness about CGRP Inhibitors, and the launch of new and innovative products.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

CGRP Inhibitor Market Indication Insights

The CGRP Inhibitor Market is segmented by Indication into Migraine and Cluster Headache. Migraine is the most common type of headache, affecting over 1 billion people worldwide. Cluster Headache is a severe type of headache that occurs in clusters, with each cluster lasting for several weeks or months. The Migraine segment is expected to account for the largest share of the CGRP Inhibitor Market in 2023, owing to the high prevalence of migraine and the availability of a wide range of CGRP Inhibitors for the treatment of migraine.

CGRP Inhibitor Market Route of Administration Insights

The CGRP Inhibitor Market, segmented by Route of Administration, comprises Subcutaneous and Intravenous routes. Subcutaneous administration dominates the market, accounting for a larger share of CGRP Inhibitor Market revenue in 2023. It offers advantages such as self-administration, ease of use, and reduced injection-related pain, making it a preferred choice for patients.

Intravenous administration, while less common, is used in situations where rapid onset of action is required, such as in acute migraine attacks. The CGRP Inhibitor Market data indicates that the Subcutaneous segment is projected to maintain its dominance throughout the forecast period, driven by the increasing adoption of self-injectable therapies and the availability of user-friendly devices.

The Intravenous segment, though smaller, is expected to grow steadily, supported by advancements in infusion technology and the introduction of new IV-administered CGRP Inhibitors.

CGRP Inhibitor Market Mechanism of Action Insights

The CGRP Inhibitor Market is segmented based on Mechanism of Action into Anti-CGRP Ligand and CGRP Receptor Antagonist. In 2023, the Anti-CGRP Ligand segment held the largest market share of 60.5%, and it is expected to maintain its dominance throughout the forecast period. The growth of this segment can be attributed to the increasing adoption of anti-CGRP ligand therapies for the treatment of migraine and cluster headache.

The CGRP Receptor Antagonist segment is expected to witness a significant growth rate during the forecast period, owing to the rising prevalence of migraine and cluster headache, along with the increasing awareness about CGRP receptor antagonists.

CGRP Inhibitor Market Regional Insights

The CGRP Inhibitor Market is segmented into North America, Europe, APAC, South America, and MEA. Among these regions, North America is expected to hold the largest market share in 2023, owing to the presence of a large number of pharmaceutical companies and research institutes in the region. Europe is expected to be the second-largest market, followed by APAC.

APAC is expected to witness the highest growth rate during the forecast period, owing to the increasing prevalence of migraine and cluster headache in the region. The CGRP Inhibitor Market is expected to grow from USD 0.917 billion in 2023 to USD 2.617 billion by 2032, at a CAGR of 12.33%.

The growth of the market is attributed to the increasing prevalence of migraine and cluster headache, the rising demand for effective and safe treatments, and the launch of new and innovative products.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

CGRP Inhibitor Market Key Players and Competitive Insights

Major players in CGRP Inhibitor Market industry are continuously investing in research and development to bring innovative products to the market. The CGRP Inhibitor Market development pipeline is robust, with several promising candidates in late-stage clinical trials. This is expected to drive the growth of the CGRP Inhibitor Market in the coming years.

Leading CGRP Inhibitor Market players are also focusing on expanding their geographical presence through strategic partnerships and acquisitions. This is expected to further intensify the competition in the CGRP Inhibitor Market. The Competitive Landscape of the CGRP Inhibitor Market is expected to remain dynamic in the coming years, with new entrants and established players vying for market share.

A leading CGRP Inhibitor Market player is Novartis. The company's CGRP Inhibitor, Aimovig, was the first FDA-approved drug for the prevention of chronic migraine. Aimovig has been commercially successful, and it has helped Novartis to establish a strong position in the CGRP Inhibitor Market.

The company is also developing other CGRP Inhibitors, which are expected to further strengthen its position in the market. A major CGRP Inhibitor Market competitor is Amgen. The company's CGRP Inhibitor, erenumab (Aimovig), is also FDA-approved for the prevention of chronic migraine.

Erenumab has been shown to be effective in reducing the frequency and severity of migraine attacks. Amgen is also developing other CGRP Inhibitors, which are expected to further strengthen its position in the CGRP Inhibitor Market.

Key Companies in the CGRP Inhibitor Market Include

• Lundbeck
• AstraZeneca plc
• Allergan plc
• AbbVie Inc.
• Amgen
• Merck Co., Inc.
• F. HoffmannLa Roche Ltd
• Novartis AG
• Biogen Inc.
• GlaxoSmithKline plc
• BristolMyers Squibb Company
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Eli Lilly and Company

CGRP Inhibitor Market Industry Developments

The CGRP Inhibitor market is expected to witness significant growth in the coming years, driven by the increasing prevalence of migraine and cluster headache disorders. In 2023, the market was valued at USD 2.39 billion and is projected to reach USD 6.8 billion by 2032, exhibiting a CAGR of 12.33%. Key players in the market include Amgen, Eli Lilly, Teva Pharmaceutical Industries, and Allergan.

Recent developments in the market include the approval of new CGRP Inhibitors, such as rimegepant and atogepant, and the expansion of existing product portfolios by major players. Additionally, the growing adoption of telemedicine and the increasing awareness of CGRP Inhibitors among healthcare professionals are expected to contribute to the market growth.

CGRP Inhibitor Market Segmentation Insights

CGRP Inhibitor Market Type of Inhibitor Outlook

• Monoclonal Antibodies
• Small Molecules
• Peptides

CGRP Inhibitor Market Indication Outlook

• Migraine
• Cluster Headache

CGRP Inhibitor Market Route of Administration Outlook

• Subcutaneous
• Intravenous

CGRP Inhibitor Market Mechanism of Action Outlook

• Anti-CGRP Ligand
• CGRP Receptor Antagonist

CGRP Inhibitor Market Regional Outlook

• North America
• Europe
• South America
• Asia Pacific
• Middle East and Africa

CGRP Inhibitor Market Segmentation

• CGRP Inhibitor Market By Type of Inhibitor (USD Billion, 2019-2032)

  • Monoclonal Antibodies

  • Small Molecules

  • Peptides

• CGRP Inhibitor Market By Indication (USD Billion, 2019-2032)

  • Migraine

  • Cluster Headache

• CGRP Inhibitor Market By Route of Administration (USD Billion, 2019-2032)

  • Subcutaneous

  • Intravenous

• CGRP Inhibitor Market By Mechanism of Action (USD Billion, 2019-2032)

  • Anti-CGRP Ligand

  • CGRP Receptor Antagonist

• CGRP Inhibitor Market By Regional (USD Billion, 2019-2032)

  • North America

  • Europe

  • South America

  • Asia Pacific

  • Middle East and Africa

CGRP Inhibitor Market Regional Outlook (USD Billion, 2019-2032)

• North America Outlook (USD Billion, 2019-2032)

  • North America CGRP Inhibitor Market by Type of Inhibitor Type

    • Monoclonal Antibodies

    • Small Molecules

    • Peptides

  • North America CGRP Inhibitor Market by Indication Type

    • Migraine

    • Cluster Headache

  • North America CGRP Inhibitor Market by Route of Administration Type

    • Subcutaneous

    • Intravenous

  • North America CGRP Inhibitor Market by Mechanism of Action Type

    • Anti-CGRP Ligand

    • CGRP Receptor Antagonist

  • North America CGRP Inhibitor Market by Regional Type

    • US

    • Canada

  • US Outlook (USD Billion, 2019-2032)

  • US CGRP Inhibitor Market by Type of Inhibitor Type

    • Monoclonal Antibodies

    • Small Molecules

    • Peptides

  • US CGRP Inhibitor Market by Indication Type

    • Migraine

    • Cluster Headache

  • US CGRP Inhibitor Market by Route of Administration Type

    • Subcutaneous

    • Intravenous

  • US CGRP Inhibitor Market by Mechanism of Action Type

    • Anti-CGRP Ligand

    • CGRP Receptor Antagonist

  • CANADA Outlook (USD Billion, 2019-2032)

  • CANADA CGRP Inhibitor Market by Type of Inhibitor Type

    • Monoclonal Antibodies

    • Small Molecules

    • Peptides

  • CANADA CGRP Inhibitor Market by Indication Type

    • Migraine

    • Cluster Headache

  • CANADA CGRP Inhibitor Market by Route of Administration Type

    • Subcutaneous

    • Intravenous

  • CANADA CGRP Inhibitor Market by Mechanism of Action Type

    • Anti-CGRP Ligand

    • CGRP Receptor Antagonist

• Europe Outlook (USD Billion, 2019-2032)

  • Europe CGRP Inhibitor Market by Type of Inhibitor Type

    • Monoclonal Antibodies

    • Small Molecules

    • Peptides

  • Europe CGRP Inhibitor Market by Indication Type

    • Migraine

    • Cluster Headache

  • Europe CGRP Inhibitor Market by Route of Administration Type

    • Subcutaneous

    • Intravenous

  • Europe CGRP Inhibitor Market by Mechanism of Action Type

    • Anti-CGRP Ligand

    • CGRP Receptor Antagonist

  • Europe CGRP Inhibitor Market by Regional Type

    • Germany

    • UK

    • France

    • Russia

    • Italy

    • Spain

    • Rest of Europe

  • GERMANY Outlook (USD Billion, 2019-2032)

  • GERMANY CGRP Inhibitor Market by Type of Inhibitor Type

    • Monoclonal Antibodies

    • Small Molecules

    • Peptides

  • GERMANY CGRP Inhibitor Market by Indication Type

    • Migraine

    • Cluster Headache

  • GERMANY CGRP Inhibitor Market by Route of Administration Type

    • Subcutaneous

    • Intravenous

  • GERMANY CGRP Inhibitor Market by Mechanism of Action Type

    • Anti-CGRP Ligand

    • CGRP Receptor Antagonist

  • UK Outlook (USD Billion, 2019-2032)

  • UK CGRP Inhibitor Market by Type of Inhibitor Type

    • Monoclonal Antibodies

    • Small Molecules

    • Peptides

  • UK CGRP Inhibitor Market by Indication Type

    • Migraine

    • Cluster Headache

  • UK CGRP Inhibitor Market by Route of Administration Type

    • Subcutaneous

    • Intravenous

  • UK CGRP Inhibitor Market by Mechanism of Action Type

    • Anti-CGRP Ligand

    • CGRP Receptor Antagonist

  • FRANCE Outlook (USD Billion, 2019-2032)

  • FRANCE CGRP Inhibitor Market by Type of Inhibitor Type

    • Monoclonal Antibodies

    • Small Molecules

    • Peptides

  • FRANCE CGRP Inhibitor Market by Indication Type

    • Migraine

    • Cluster Headache

  • FRANCE CGRP Inhibitor Market by Route of Administration Type

    • Subcutaneous

    • Intravenous

  • FRANCE CGRP Inhibitor Market by Mechanism of Action Type

    • Anti-CGRP Ligand

    • CGRP Receptor Antagonist

  • RUSSIA Outlook (USD Billion, 2019-2032)

  • RUSSIA CGRP Inhibitor Market by Type of Inhibitor Type

    • Monoclonal Antibodies

    • Small Molecules

    • Peptides

  • RUSSIA CGRP Inhibitor Market by Indication Type

    • Migraine

    • Cluster Headache

  • RUSSIA CGRP Inhibitor Market by Route of Administration Type

    • Subcutaneous

    • Intravenous

  • RUSSIA CGRP Inhibitor Market by Mechanism of Action Type

    • Anti-CGRP Ligand

    • CGRP Receptor Antagonist

  • ITALY Outlook (USD Billion, 2019-2032)

  • ITALY CGRP Inhibitor Market by Type of Inhibitor Type

    • Monoclonal Antibodies

    • Small Molecules

    • Peptides

  • ITALY CGRP Inhibitor Market by Indication Type

    • Migraine

    • Cluster Headache

  • ITALY CGRP Inhibitor Market by Route of Administration Type

    • Subcutaneous

    • Intravenous

  • ITALY CGRP Inhibitor Market by Mechanism of Action Type

    • Anti-CGRP Ligand

    • CGRP Receptor Antagonist

  • SPAIN Outlook (USD Billion, 2019-2032)

  • SPAIN CGRP Inhibitor Market by Type of Inhibitor Type

    • Monoclonal Antibodies

    • Small Molecules

    • Peptides

  • SPAIN CGRP Inhibitor Market by Indication Type

    • Migraine

    • Cluster Headache

  • SPAIN CGRP Inhibitor Market by Route of Administration Type

    • Subcutaneous

    • Intravenous

  • SPAIN CGRP Inhibitor Market by Mechanism of Action Type

    • Anti-CGRP Ligand

    • CGRP Receptor Antagonist

  • REST OF EUROPE Outlook (USD Billion, 2019-2032)

  • REST OF EUROPE CGRP Inhibitor Market by Type of Inhibitor Type

    • Monoclonal Antibodies

    • Small Molecules

    • Peptides

  • REST OF EUROPE CGRP Inhibitor Market by Indication Type

    • Migraine

    • Cluster Headache

  • REST OF EUROPE CGRP Inhibitor Market by Route of Administration Type

    • Subcutaneous

    • Intravenous

  • REST OF EUROPE CGRP Inhibitor Market by Mechanism of Action Type

    • Anti-CGRP Ligand

    • CGRP Receptor Antagonist

• APAC Outlook (USD Billion, 2019-2032)

  • APAC CGRP Inhibitor Market by Type of Inhibitor Type

    • Monoclonal Antibodies

    • Small Molecules

    • Peptides

  • APAC CGRP Inhibitor Market by Indication Type

    • Migraine

    • Cluster Headache

  • APAC CGRP Inhibitor Market by Route of Administration Type

    • Subcutaneous

    • Intravenous

  • APAC CGRP Inhibitor Market by Mechanism of Action Type

    • Anti-CGRP Ligand

    • CGRP Receptor Antagonist

  • APAC CGRP Inhibitor Market by Regional Type

    • China

    • India

    • Japan

    • South Korea

    • Malaysia

    • Thailand

    • Indonesia

    • Rest of APAC

  • CHINA Outlook (USD Billion, 2019-2032)

  • CHINA CGRP Inhibitor Market by Type of Inhibitor Type

    • Monoclonal Antibodies

    • Small Molecules

    • Peptides

  • CHINA CGRP Inhibitor Market by Indication Type

    • Migraine

    • Cluster Headache

  • CHINA CGRP Inhibitor Market by Route of Administration Type

    • Subcutaneous

    • Intravenous

  • CHINA CGRP Inhibitor Market by Mechanism of Action Type

    • Anti-CGRP Ligand

    • CGRP Receptor Antagonist

  • INDIA Outlook (USD Billion, 2019-2032)

  • INDIA CGRP Inhibitor Market by Type of Inhibitor Type

    • Monoclonal Antibodies

    • Small Molecules

    • Peptides

  • INDIA CGRP Inhibitor Market by Indication Type

    • Migraine

    • Cluster Headache

  • INDIA CGRP Inhibitor Market by Route of Administration Type

    • Subcutaneous

    • Intravenous

  • INDIA CGRP Inhibitor Market by Mechanism of Action Type

    • Anti-CGRP Ligand

    • CGRP Receptor Antagonist

  • JAPAN Outlook (USD Billion, 2019-2032)

  • JAPAN CGRP Inhibitor Market by Type of Inhibitor Type

    • Monoclonal Antibodies

    • Small Molecules

    • Peptides

  • JAPAN CGRP Inhibitor Market by Indication Type

    • Migraine

    • Cluster Headache

  • JAPAN CGRP Inhibitor Market by Route of Administration Type

    • Subcutaneous

    • Intravenous

  • JAPAN CGRP Inhibitor Market by Mechanism of Action Type

    • Anti-CGRP Ligand

    • CGRP Receptor Antagonist

  • SOUTH KOREA Outlook (USD Billion, 2019-2032)

  • SOUTH KOREA CGRP Inhibitor Market by Type of Inhibitor Type

    • Monoclonal Antibodies

    • Small Molecules

    • Peptides

  • SOUTH KOREA CGRP Inhibitor Market by Indication Type

    • Migraine

    • Cluster Headache

  • SOUTH KOREA CGRP Inhibitor Market by Route of Administration Type

    • Subcutaneous

    • Intravenous

  • SOUTH KOREA CGRP Inhibitor Market by Mechanism of Action Type

    • Anti-CGRP Ligand

    • CGRP Receptor Antagonist

  • MALAYSIA Outlook (USD Billion, 2019-2032)

  • MALAYSIA CGRP Inhibitor Market by Type of Inhibitor Type

    • Monoclonal Antibodies

    • Small Molecules

    • Peptides

  • MALAYSIA CGRP Inhibitor Market by Indication Type

    • Migraine

    • Cluster Headache

  • MALAYSIA CGRP Inhibitor Market by Route of Administration Type

    • Subcutaneous

    • Intravenous

  • MALAYSIA CGRP Inhibitor Market by Mechanism of Action Type

    • Anti-CGRP Ligand

    • CGRP Receptor Antagonist

  • THAILAND Outlook (USD Billion, 2019-2032)

  • THAILAND CGRP Inhibitor Market by Type of Inhibitor Type

    • Monoclonal Antibodies

    • Small Molecules

    • Peptides

  • THAILAND CGRP Inhibitor Market by Indication Type

    • Migraine

    • Cluster Headache

  • THAILAND CGRP Inhibitor Market by Route of Administration Type

    • Subcutaneous

    • Intravenous

  • THAILAND CGRP Inhibitor Market by Mechanism of Action Type

    • Anti-CGRP Ligand

    • CGRP Receptor Antagonist

  • INDONESIA Outlook (USD Billion, 2019-2032)

  • INDONESIA CGRP Inhibitor Market by Type of Inhibitor Type

    • Monoclonal Antibodies

    • Small Molecules

    • Peptides

  • INDONESIA CGRP Inhibitor Market by Indication Type

    • Migraine

    • Cluster Headache

  • INDONESIA CGRP Inhibitor Market by Route of Administration Type

    • Subcutaneous

    • Intravenous

  • INDONESIA CGRP Inhibitor Market by Mechanism of Action Type

    • Anti-CGRP Ligand

    • CGRP Receptor Antagonist

  • REST OF APAC Outlook (USD Billion, 2019-2032)

  • REST OF APAC CGRP Inhibitor Market by Type of Inhibitor Type

    • Monoclonal Antibodies

    • Small Molecules

    • Peptides

  • REST OF APAC CGRP Inhibitor Market by Indication Type

    • Migraine

    • Cluster Headache

  • REST OF APAC CGRP Inhibitor Market by Route of Administration Type

    • Subcutaneous

    • Intravenous

  • REST OF APAC CGRP Inhibitor Market by Mechanism of Action Type

    • Anti-CGRP Ligand

    • CGRP Receptor Antagonist

• South America Outlook (USD Billion, 2019-2032)

  • South America CGRP Inhibitor Market by Type of Inhibitor Type

    • Monoclonal Antibodies

    • Small Molecules

    • Peptides

  • South America CGRP Inhibitor Market by Indication Type

    • Migraine

    • Cluster Headache

  • South America CGRP Inhibitor Market by Route of Administration Type

    • Subcutaneous

    • Intravenous

  • South America CGRP Inhibitor Market by Mechanism of Action Type

    • Anti-CGRP Ligand

    • CGRP Receptor Antagonist

  • South America CGRP Inhibitor Market by Regional Type

    • Brazil

    • Mexico

    • Argentina

    • Rest of South America

  • BRAZIL Outlook (USD Billion, 2019-2032)

  • BRAZIL CGRP Inhibitor Market by Type of Inhibitor Type

    • Monoclonal Antibodies

    • Small Molecules

    • Peptides

  • BRAZIL CGRP Inhibitor Market by Indication Type

    • Migraine

    • Cluster Headache

  • BRAZIL CGRP Inhibitor Market by Route of Administration Type

    • Subcutaneous

    • Intravenous

  • BRAZIL CGRP Inhibitor Market by Mechanism of Action Type

    • Anti-CGRP Ligand

    • CGRP Receptor Antagonist

  • MEXICO Outlook (USD Billion, 2019-2032)

  • MEXICO CGRP Inhibitor Market by Type of Inhibitor Type

    • Monoclonal Antibodies

    • Small Molecules

    • Peptides

  • MEXICO CGRP Inhibitor Market by Indication Type

    • Migraine

    • Cluster Headache

  • MEXICO CGRP Inhibitor Market by Route of Administration Type

    • Subcutaneous

    • Intravenous

  • MEXICO CGRP Inhibitor Market by Mechanism of Action Type

    • Anti-CGRP Ligand

    • CGRP Receptor Antagonist

  • ARGENTINA Outlook (USD Billion, 2019-2032)

  • ARGENTINA CGRP Inhibitor Market by Type of Inhibitor Type

    • Monoclonal Antibodies

    • Small Molecules

    • Peptides

  • ARGENTINA CGRP Inhibitor Market by Indication Type

    • Migraine

    • Cluster Headache

  • ARGENTINA CGRP Inhibitor Market by Route of Administration Type

    • Subcutaneous

    • Intravenous

  • ARGENTINA CGRP Inhibitor Market by Mechanism of Action Type

    • Anti-CGRP Ligand

    • CGRP Receptor Antagonist

  • REST OF SOUTH AMERICA Outlook (USD Billion, 2019-2032)

  • REST OF SOUTH AMERICA CGRP Inhibitor Market by Type of Inhibitor Type

    • Monoclonal Antibodies

    • Small Molecules

    • Peptides

  • REST OF SOUTH AMERICA CGRP Inhibitor Market by Indication Type

    • Migraine

    • Cluster Headache

  • REST OF SOUTH AMERICA CGRP Inhibitor Market by Route of Administration Type

    • Subcutaneous

    • Intravenous

  • REST OF SOUTH AMERICA CGRP Inhibitor Market by Mechanism of Action Type

    • Anti-CGRP Ligand

    • CGRP Receptor Antagonist

• MEA Outlook (USD Billion, 2019-2032)

  • MEA CGRP Inhibitor Market by Type of Inhibitor Type

    • Monoclonal Antibodies

    • Small Molecules

    • Peptides

  • MEA CGRP Inhibitor Market by Indication Type

    • Migraine

    • Cluster Headache

  • MEA CGRP Inhibitor Market by Route of Administration Type

    • Subcutaneous

    • Intravenous

  • MEA CGRP Inhibitor Market by Mechanism of Action Type

    • Anti-CGRP Ligand

    • CGRP Receptor Antagonist

  • MEA CGRP Inhibitor Market by Regional Type

    • GCC Countries

    • South Africa

    • Rest of MEA

  • GCC COUNTRIES Outlook (USD Billion, 2019-2032)

  • GCC COUNTRIES CGRP Inhibitor Market by Type of Inhibitor Type

    • Monoclonal Antibodies

    • Small Molecules

    • Peptides

  • GCC COUNTRIES CGRP Inhibitor Market by Indication Type

    • Migraine

    • Cluster Headache

  • GCC COUNTRIES CGRP Inhibitor Market by Route of Administration Type

    • Subcutaneous

    • Intravenous

  • GCC COUNTRIES CGRP Inhibitor Market by Mechanism of Action Type

    • Anti-CGRP Ligand

    • CGRP Receptor Antagonist

  • SOUTH AFRICA Outlook (USD Billion, 2019-2032)

  • SOUTH AFRICA CGRP Inhibitor Market by Type of Inhibitor Type

    • Monoclonal Antibodies

    • Small Molecules

    • Peptides

  • SOUTH AFRICA CGRP Inhibitor Market by Indication Type

    • Migraine

    • Cluster Headache

  • SOUTH AFRICA CGRP Inhibitor Market by Route of Administration Type

    • Subcutaneous

    • Intravenous

  • SOUTH AFRICA CGRP Inhibitor Market by Mechanism of Action Type

    • Anti-CGRP Ligand

    • CGRP Receptor Antagonist

  • REST OF MEA Outlook (USD Billion, 2019-2032)

  • REST OF MEA CGRP Inhibitor Market by Type of Inhibitor Type

    • Monoclonal Antibodies

    • Small Molecules

    • Peptides

  • REST OF MEA CGRP Inhibitor Market by Indication Type

    • Migraine

    • Cluster Headache

  • REST OF MEA CGRP Inhibitor Market by Route of Administration Type

    • Subcutaneous

    • Intravenous

  • REST OF MEA CGRP Inhibitor Market by Mechanism of Action Type

    • Anti-CGRP Ligand

    • CGRP Receptor Antagonist